Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13137987 | 1.00 | SLC6A9 (0.44) | SLC6A9CYP2C9 | |
| SCHEMBL8243232 | 0.88 | SLC6A9 (0.39) | SLC6A9 | |
| SCHEMBL13137911 | 0.88 | SLC6A9 (0.39) | SLC6A9 | |
| SCHEMBL13137990 | 0.88 | SLC6A9 (0.39) | SLC6A9CYP2C9 | |
| SCHEMBL13138010 | 0.88 | SLC6A9 (0.39) | SLC6A9CYP2C9 | |
| SCHEMBL13138006 | 0.88 | SLC6A9 (0.39) | SLC6A9CYP2C9 | |
| SCHEMBL13137980 | 0.86 | SLC6A9 (0.47) | SLC6A9 | |
| SCHEMBL13137991 | 0.85 | SLC6A9 (0.44) | SLC6A9CYP2C9 | |
| SCHEMBL13137989 | 0.85 | SLC6A9 (0.44) | SLC6A9CYP2C9 | |
| SCHEMBL13137997 | 0.83 | SLC6A9 (0.51) | SLC6A9CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222317-A1 | Azetidine Derivatives as GlyT1 Inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222317-A1 | Azetidine Derivatives as GlyT1 Inhibitors | GRIA1, GLRA1, GRIN1 | SLC6A9 18/4885CYP2C9 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.